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Background:  Challenges  in  reaching  good  vaccination  coverage  against  measles  emerged  in  several  Euro-
pean  Union/European  Economic  Area  Member  States  (EU/EEA  MS)  leading  to progressive  accumulation  of
susceptible  individuals  and  outbreaks.  The  Burden  of  Communicable  Diseases  in  Europe  (BCoDE)  project
developed  a methodology  for measuring  the burden  of communicable  diseases  expressed  in Disability-
Adjusted  Life  Years  (DALYs)  in the EU/EEA  MS.  The  aim of this  study  was  to  compare  national  vaccination
coverage  and  burden  of  measles  across  EU/EEA  MS.
Methods: Country-speciﬁc  data  on measles  national  vaccination  coverage  2006–2011  from  29  EU/EEA MS
(MCV1)  were  retrieved  from  Centralized  Information  System  for  Infectious  Diseases  (CISID).  DALYs were
calculated  for  each  country  separately  using  a disease  progression  model  with  a single input  parameter
(annual  measles  incidence,  adjusted  for under-estimation).  A  software  application  was  used to  com-
pute  estimated  DALYs  according  to  country-speciﬁc  and  year-speciﬁc  population  age-distributions  (data
retrieved  from  Eurostat).  Log-linear  mixed-effect  regression  modeling  approach  was  used  to investigate
a  linear  relation  between  natural  logarithm-transformed  DALYs  and  coverage.
Results: The  reported  annual  vaccination  coverage  ranged  from  72.6%  to  100%.  The  estimated  national
annual  burden  ranged  from  0  to 30.6  DALYs/100,000.  Adjusting  for year,  there  was  a  signiﬁcant  negative
relationship  between  coverage  and burden.  For  a given  country  there  was  a decrease  in log-transformed
DALYs/100,000  of 0.025  (95%  conﬁdence  interval:  −0.047  to −0.003)  for every  percentage  increase  in
vaccination  coverage.  The  largest  effect  of  calendar  time  on  estimated  burden  of measles  was observed
for  the  year  2011,  the smallest  was  for the  year  2007.
Conclusions: This  study  shows  that  the  degree  of  success  of national  measles  vaccination  programs,  when
measured  by  the  coverage  obtained,  is signiﬁcantly  associated  with  overall  impact  of  measles  across
EU/EEA  MS.  In EU/EEA  MS  each  percentage  point  increase  in  national  vaccination  coverage  seems  to  lead
to  early  signiﬁcant  reduction  of overall  burden  of  measles.. Introduction
A comprehensive assessment of the overall impact of a disease
equires information not only on its occurrence, but also on sever-
ty, disease-related mortality, and morbidity due to the sequelae of
he disease. Several composite health measures, or summary meas-
res of population health, have been developed for this purpose,
nd many projects and studies have been carried out globally in
he last few decades to reach the goal of assessing the burden of
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disease by taking into account all of these aspects of disease impact
[1–7].
In order to gain insight into the overall impact of communica-
ble diseases on population health in Europe and to support health
policy-making, in 2009 the European Centre for Disease Prevention
and Control (ECDC) initiated the Burden of Communicable Dis-
eases in Europe (BCoDE) project. The BCoDE project developed a
methodology and a software application (BCoDE toolkit) for mea-
suring the current and future burden of communicable diseases in
the European Union and European Economic Area Member States
(EU/EEA MS). The burden of communicable diseases was obtained
through a pathogen-based and incidence-based approach, which
allows for the calculation of Disability-Adjusted Life Years (DALYs)
cine 32
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or 32 infectious diseases under ECDC’s remit, including measles
8,9].
Measles is a highly infectious disease and about 90% of individ-
als would be infected by the age of 10 in the absence of vaccination
10,11]. With the resolution of 16th September 2010, all countries
n the European Region of the World Health Organization (WHO),
hich includes EU/EEA MS,  have renewed their commitment to
liminate measles and rubella by 2015, and have identiﬁed essen-
ial criteria for elimination of measles and rubella in the WHO
uropean region, including the demonstrated protection of at least
5% of the population against measles and rubella [12–14]. Chal-
enges in reaching good vaccination coverage have emerged in
everal EU/EEA MS  leading to progressive accumulation of sus-
eptible individuals, loss of heard immunity and several outbreaks
f measles across Europe in recent years [11,15–19]. These chal-
enges are due, among other reasons, to the reluctance of speciﬁc
ubgroups of the population to undergo vaccination, and to the
ifﬁculty in reaching speciﬁc communities [20–24].
Previous studies have investigated the relationship between the
ncidence of measles, or the likelihood of new outbreaks, and the
accination coverage of a population [25–28]; however, no studies
o our knowledge have studied the relationship between vaccina-
ion coverage across EU/EEA MS  and the burden of measles using
ALYs. In this study we wanted to investigate the effect of vacci-
ation programs on the burden of measles in Europe. In order to
each this goal we compared measles national vaccination cover-
ge and burden of measles expressed in DALYs across EU/EEA MS
nd studied their correlation in the period 2006–2011.
. Methods
We  obtained measles incidence and vaccination coverage data
or 29 EU/EEA MS,  from 1998 through 2011 inclusive. Age-group
peciﬁc incidence data were available from The European Surveil-
ance System (TESSy), an European database held by ECDC [29].
he incidence data reported to TESSy were corrected for under-
stimation by applying a multiplication factor of 2.5 as suggested
y Stein et al., under the assumption that EU/EEA MS  have good
easles control [6]. Vaccination coverage (MCV1; measles con-
aining vaccine, ﬁrst dose) was obtained from WHO’s Centralized
nformation System for Infectious Diseases (CISID) [30]. Country
ames were anonymised before analysis.
Because of extensive missing coverage data and the sparse avail-
bility of incidence data before 2006, the dataset was  reduced by
estricting to the period 2006–2011. For 14 countries, vaccination
overage for one or more years in the period 2006–2011 was  miss-
ng; these missing values were imputed using the previous year’s
alue (or the value from two or more years previous, if the previ-
us year’s value was also missing); 13.8% (24/174) of vaccination
overage values were consequently imputed.
.1. DALY calculation
The  DALY is a standard summary measure of population health
btained by adding two independent quantities: years of life lost
ue to premature mortality (YLL), which reﬂect the mortality
ontribution of a certain disease or condition, and years of life
ived with a disability (YLD), which account for the morbidity
f the disease or condition under study. DALYs were calcu-
ated for each country separately using a disease natural history
odel with a single input parameter (annual measles incidence,
djusted for under-estimation) and the “BCoDE toolkit” software
pplication was used to compute estimated DALYs according
o country-speciﬁc and year-speciﬁc population age-distributions
data retrieved from Eurostat) [31]. (2014) 1814–1819 1815
The  measles disease model was  created from the information
collected through an extensive literature review and via consul-
tation with measles experts, by linking the incidence of measles
to all possible sequelae (health outcomes) through a disease pro-
gression model, or outcome tree. Health outcomes were considered
part of the outcome tree if there was evidence of a causal rela-
tionship between measles and the health outcome (Fig. 1). In the
disease burden calculations, years of life lost (YLL) were estimated
using the Standard Expected Years of Life Lost (SEYLL) based on
the highest observed life expectancy, which is that of the Japanese
population. The Japanase population has been commonly used
as a standard population in DALYs calculations since it has the
longest life expectancy, so that in principle every human being
can be expected to live at least as long [32–36]. Data on mortality
were embedded into the model and were taken from both national
sources and Eurostat [31]. Severity weights (i.e., disability weights)
for non-fatal health outcomes were obtained from the Global Bur-
den of Disease (GBD) study [2,5]. In conditions for which no weights
existed, weights were adapted from existing GBD severity weights
for similar conditions. Transition probabilities and mean duration
of each health outcome were derived from the literature review.
Time discounting and age-weighting were not applied in the base
case analysis. The modeling approach applied assumed a steady-
state and is therefore not suitable for forecasting of burden.
Information on gender was not provided, so cases were dis-
tributed evenly between males and females in each age group.
Cases (<1%) for which information on age was missing were not
included in the analysis.
2.2.  Statistical modeling
Our  dataset consists of time-series cross-sectional data [28],
and therefore appropriate methods are required given the non-
independence of observations. We  used log-linear mixed-effect
regression modeling approach to investigate a linear relation
between natural logarithm-transformed outcome and predictor
variables. The outcome variable was  burden (in DALYs per 100,000
persons, transformed using log(DALYs + 1)), and the primary pre-
dictor variable was vaccination coverage (coded as a percentage).
We assumed all cases in a given year, t, relate to the ability of
the vaccination program to immunize the target population, esti-
mated by using vaccination coverage with MCV1 in the same year.
A Hausman test was  conducted to assess the appropriateness of
specifying country as a random instead of a ﬁxed effect, and the
need to include year as an additional ﬁxed effect was assessed
using a Lagrange multiplier test. Based on the tests, year was  ﬁtted
as dummy-coded ﬁxed effect, and country was ﬁtted as a random
effect. By specifying a random intercept for country, unexplained
heterogeneity between countries is taken into consideration (i.e.,
burden values for a given country across years are more similar
to each other than compared with other countries). As the sin-
gle coefﬁcient for coverage aggregates both between-country and
within-country effects (i.e., time-invariant and time-varying com-
ponents), a test for equality of these parameters was  conducted
before ﬁnal model speciﬁcation [37,38].
Thus, we ﬁtted a linear mixed-effects regression model with two
ﬁxed effects (coverage and year) and one random effect (country).
Model ﬁtting and inference were carried out using the plm package
[39] for the R statistical computing environment [40].
3.  ResultsMCV1 was  recommended by all national vaccination calendars
to occur during the second year of life [41]. The reported annual
MCV1 vaccination coverage ranged from 72.6% to 100%. The country
1816 E. Colzani et al. / Vaccine 32 (2014) 1814–1819
Table  1
Median vaccination coverage (with interquartile range [IQR]), median estimated disease burden (with IQR), and median age-group of cases, for each year in the period
2006–2011.
Year Median coverage (IQR) Median DALYs per 100,000 (IQR) Median age (years) of
cases  (IQR)
2006 95.4 (91.0–96.7) 0.03 (0.00–0.57) 7.5 (3–17.5)
2007  95.5 (91.9–97.0) 0.01 (0.00–0.47) 7.5 (3–17.5)
2008  96.0 (89.0–97.0) 0.05 (0.00–0.61) 17.5 (7.5–22.5)
2009  95.4 (90.4–96.7) 0.01 (0.00–0.29) 12.5 (3–17.5)
0.03 (0.00–0.71) 17.5 (7.5–22.5)
0.52 (0.07–1.76) 12.5 (3–22.5)
0.07 (0.00–0.59) 12.5 (3–22.5)
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Table 2
Coefﬁcients from the ﬁtted mixed-effects regression model (year and coverage spec-
iﬁed as ﬁxed effects; country speciﬁed as a random effect), with 95% conﬁdence
intervals  (CI).
Variable Coeff. 95% CI interval
Vaccination coverage −0.025 −0.047–−0.003
Year
2006 Reference –
2007 −0.118 −0.383–0.147
2008 0.047 −0.215–0.311
2009 0.049 −0.214–0.311
2010 0.099 −0.167–0.364
F
t2010  95.1 (91.6–96.2) 
2011  95.0 (92.0–97.0)
Overall  95.0 (88.0–97.0) 
ith the highest national coverage, averaged over the study period,
eached a proportion of 99.7%. The calculated national annual bur-
en of measles ranged from 0 to 30.6 DALYs/100,000, with the
reatest burden in a country across the study period being 7.90
ALYs/100,000/year.
Table 1 shows the median vaccination coverage, the median
ALYs per 100,000 and the median age group of the cases over
ll countries by calendar year. The year with the highest reported
accination coverage was 2008 with 96.0% of children being admin-
stered a ﬁrst dose of measles vaccine. The year with the greatest
edian burden was the year 2011 with 0.52 DALYs/100,000/year
s compared to 2007 and 2009 being the years with the lowest
edian burden (0.01 DALYs/100,000/year). The median age of the
ases was 7.5 years (interquartile range: 3–17.5) years for 2006 and
007 while it slightly increased in the following years. The mean
ge of measles cases over the whole time period was  12.5 years
interquartile range: 3–22.5).
Table 2 shows the ﬁtted model coefﬁcients. Adjusting for year,
here was a signiﬁcant negative relationship between coverage
nd burden; for a given country there was a decrease in log-
ransformed DALYs/100,000 of 0.025 (95% conﬁdence interval:
0.047 to −0.003) for every percentage point increase in vacci-
ation coverage. Compared with 2006, the burden in 2011 was
igniﬁcantly larger by 0.46 log DALYs/100,000 (95% CI: 0.20–0.73).
ig. 1. Disease progression model for measles. Complicated health states include pneumon
is SSPE = Subacute Sclerosing Panencephalitis.2011 0.464 0.201–0.726
Intercept 2.66 0.602–4.72
When using incidence of measles in a given year, and not DALYs,
as a health outcome, there was also a signiﬁcant decrease of −0.02
(95% CI: −0.046; −0.002) in log-transformed incidence/100,000 for
each percentage point increase in vaccination coverage (data not
shown).
Fig. 1 shows the measles disease progression model that was
used to calculate the DALYs. Each box represents a different
health outcome deﬁned by a speciﬁc duration (in years) and
disability weight (0 = best possible health state, 1 = worst possible
health state) (data not shown). The acute symptomatic illness is
ia, otitis media, diarrhea, convulsions, encephalitis, post-infectious encephalomyeli-
E. Colzani et al. / Vaccine 32 (2014) 1814–1819 1817
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dig. 2. Relationship between vaccination coverage and estimated disease burden (
ach  year of the study period.
ighlighted in yellow since it is where the incident measles
ases were entered into the model for the DALYs calculation. The
ossible endpoints considered were recovery (R), death (fatal
ases) and long term disabilities. The Greek letters describe the
ransition probabilities for moving from one health outcome to the
ext. The DALYs attributable to each health outcome, including
hose attributable to fatal cases, were derived through this disease
odel and eventually added in order to obtain the overall burden
f measles.
Fig. 2 plots vaccination coverage against estimated burden, sep-
rately for each year of the study period, and shows the negative
inear relationship between measles vaccination coverage and the
og burden of DALYs/100,000 by calendar year. Data points were
ore often located above 90% vaccination coverage during the
ntire study period than below. For more recent years (2009–2011)
ome observations showed high DALYs/100,000 estimates, despite
eported national vaccination coverage above 90%.
.  Discussion
Using data from a 6-year period from 29 EU/EEA MS,  we
bserved a signiﬁcant negative association between measles vac-
ination coverage and the estimated burden of measles in a given
ear. This result is in the expected direction, and importantly takes
etween-country heterogeneity in burden and time-varying effects
i.e., outbreak years) into account. Our ﬁnding is also consistent
ith the negative association recently reported between vaccina-
ion coverage and measles incidence at the global level in the period
980–2008 [28].
By  investigating the relationship between vaccination coverage
nd DALYs – as opposed to incidence – we are in fact estimating
he relationship between the success of national vaccination pro-
rammes and the estimated health burden (i.e., from both mortality
nd morbidity) attributable to infection, hence also accounting
or possible variations in the age-distribution of cases between
ountries (to which the DALY measure obtained from our disease
odel is sensitive). For instance, two countries with similar inci-
ence rates might have a very different age distribution of cases,transformed DALYs/100,000) for 29 EU/EEA Member States, plotted separately for
and  therefore will differ in estimated DALYs. In 2011, an incidence
rate of 0.06 cases/100,000 was  observed for a certain country (of
which 25.7% cases were below the age of 10 years); for the same
year, another country (74.1% cases below the age of 10 years) had
a very similar incidence rate, of 0.05 cases/100,000. The estimated
burden was  0.19 DALYS/100,000 for the ﬁrst country, but three-fold
greater, 0.65, for the second country. The current disease progres-
sion model is however unable to attribute different sets of disability
weights according to different ages at infection (i.e., measles is
assumed to have the same severity irrespective of age at infec-
tion). Therefore the presence of a positive shift in the median age at
measles infection in a population (e.g., more measles cases among
adults causing a subsequent increase of the average severity of the
disease) will not be reﬂected in the current DALYs calculation and
will possibly lead to an underestimation of the actual burden of
measles that will be larger for those countries with more suscepti-
ble adults.
We  used reported national vaccination coverage for any given
year t to estimate the quality of measles control in a given country
at a given time [6]. The use of national vaccination coverage from
the same year of measles infection in the analysis is not meant
to provide direct information on the susceptible population in a
given country at a given year. In fact, in order to perform a direct
assessment of the impact of vaccination coverage on burden of
measles, one would instead need speciﬁc information on the vacci-
nation coverage for each birth cohort rather than for each year. As
we found consistent results when running the analysis by using
as exposure variable the vaccination coverage in years prior to
measles infection, in the main analysis we decided to use coverage
and infection data from the same year.
Several measles outbreaks have been reported, in particular in
the years 2010 and 2011, when in fact more variability in the data is
apparent (Table 1), this could be consistent with the secular trend
of the disease that shows cycles of outbreaks every 6–10 years in
the vaccine era when a sufﬁcient number of susceptible individ-
uals have accumulated in the population or in subgroups of the
population [11,19]. In the latter case, outbreaks may  also in fact
arise from a country with relatively high national vaccination cov-
erage if undervaccinated pockets of the population exist. Consistent
1 cine 32
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ith epidemiological reporting, our analysis indicated the largest
baseline burden’ occurred in 2011 (i.e., the ﬁtted coefﬁcient for the
ear 2011 was 3.13 on the log scale) when rather large outbreaks
ccurred in some European countries [15]. ECDC’s 2012 Annual Epi-
emiologic Report showed continuous national outbreaks across
U/EEA MS  in 2010 and 2011 in particular, and concluded that the
enewed commitment to eliminate indigenous measles by 2015
ill probably not be achieved unless effective measures aimed at
ncreasing measles vaccination coverage are carried out [15].
This  study has some limitations. Healthcare and surveillance
ystems across EU/EEA MS  are quite heterogeneous and, although
he quality and comparability of data reported continue to improve,
ome heterogeneity in the ratio between cases of measles reported
o TESSy and the actual occurrence of measles may  be present. Cases
eported to TESSy without age information were not included;
owever, their proportion was between 0.4% and 1.2% of the total
eported cases of measles for the period 2007–2001 and of 5% in
006, so we do not believe this might have biased our ﬁndings.
lthough the authors are well aware of the recommendation of
wo doses of measles vaccination, only data on MCV1 coverage was
aken into account due to the vast heterogeneity in data availability
or MCV2 doses across EU/EEA MS.  Our dataset lacked information
or certain countries and certain years on both vaccination cover-
ge (n = 24 data points) and burden (n = 3). We  imputed the former
sing the previous years’ value, and deleted those cases missing the
atter from the statistical analysis; it is not known if results would
ary given the availability of complete data on these two variables,
lthough this is unlikely. When removing the countries with one
r more missing coverage years, the regression coefﬁcient for vac-
ination coverage was similar (−0.013) to the result we reported
coefﬁcient = −0.025). It was however no longer statistically signif-
cant (95% CI: −0.045 to 0.019), perhaps due to the smaller sample
ize and the associated reduction in statistical power.
This  study has also some relevant strengths. In order to calculate
ALYs attributed to measles, a well-deﬁned and detailed disease
rogression model (Fig. 1) that comprehensively takes into account
he possible consequences of a measles infection was used. To our
nowledge no other study to date has tried to assess the impact
f national measles vaccination coverage on the burden of measles
sing DALYs across 29 EU/EEA MS  over several years with this level
f detail. Also, the statistical approach used allowed unexplained
eterogeneity across countries to be taken into account, and so that
he non-independence of burden estimates from the same country
ithin the study period was not overlooked.
. Conclusions
In conclusion, this study shows that the higher the vaccina-
ion coverage, the lower the burden of measles, suggesting that
he degree of success of national measles vaccination programs,
hen measured by the coverage obtained, is signiﬁcantly associ-
ted with the burden of measles across EU/EEA MS.  Attaining a
igher measles vaccination coverage would thus result in impor-
ant beneﬁts in terms of early signiﬁcant reduction of the overall
mpact of measles in the population, and would put EU/EEA MS  on
he right track toward the goal of eventual elimination.
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